These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 38296594)
1. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594 [TBL] [Abstract][Full Text] [Related]
2. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. Abu-Sbeih H; Ali FS; Wang X; Mallepally N; Chen E; Altan M; Bresalier RS; Charabaty A; Dadu R; Jazaeri A; Lashner B; Wang Y J Immunother Cancer; 2019 Apr; 7(1):93. PubMed ID: 30940209 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. Zou F; Faleck D; Thomas A; Harris J; Satish D; Wang X; Charabaty A; Ernstoff MS; Glitza Oliva IC; Hanauer S; McQuade J; Obeid M; Shah A; Richards DM; Sharon E; Wolchok J; Thompson J; Wang Y J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34789551 [TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced colitis in patients with metastatic melanoma. De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207 [TBL] [Abstract][Full Text] [Related]
13. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review. Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606 [TBL] [Abstract][Full Text] [Related]
14. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205 [TBL] [Abstract][Full Text] [Related]
15. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment. Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360 [TBL] [Abstract][Full Text] [Related]
16. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. Favara DM; Spain L; Au L; Clark J; Daniels E; Diem S; Chauhan D; Turajlic S; Powell N; Larkin JM; Yousaf N ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32641348 [TBL] [Abstract][Full Text] [Related]
17. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. Brongiel S; Rychalsky KL; Luon D; Johnson AR; Price C; Abdelghany O Ann Pharmacother; 2023 Feb; 57(2):148-155. PubMed ID: 35656843 [TBL] [Abstract][Full Text] [Related]